palifosfamide-tris + carboplatin + etoposide

**palifosfamide-tris + carboplatin + etoposide** is a combination chemotherapy regimen used in clinical studies for the treatment of extensive-stage small cell lung cancer (ES-SCLC). - **Palifosfamide-tris** is a stabilized, active metabolite of ifosfamide, classified as a bi-functional DNA alkylator, designed to avoid toxic byproducts such as acrolein and chloroacetaldehyde. Palifosfamide-tris crosslinks DNA, causing cell death in rapidly dividing cancer cells. - **Carboplatin** is a platinum-based compound that forms DNA crosslinks, interfering with DNA replication and transcription, leading to apoptosis of cancer cells. - **Etoposide** is a topoisomerase II inhibitor, which causes double-stranded DNA breaks and prevents DNA repair, resulting in apoptosis. This triple regimen was studied in randomized phase III trials, notably in previously untreated ES-SCLC, with endpoints including overall survival and progression-free survival. The combination was developed and studied primarily by Alaunos Therapeutics (formerly Ziopharm Oncology). The regimen is administered intravenously in cycles (palifosfamide-tris at 130 mg/m2/day for 3 days, carboplatin at AUC 4 mg/mL/min for one day, etoposide at 100 mg/m2/day for 3 days, every 21 days up to 6 cycles). The most common adverse events reflect those of alkylating agents, platinum compounds, and topoisomerase inhibitors. Palifosfamide-tris does not lead to the toxic metabolites observed with its parent drug ifosfamide. Clinical trial data did not demonstrate superior efficacy compared to carboplatin and etoposide alone[1][3][5][7].

Other names

PaCE